NasdaqCM:TGTXBiotechs
TG Therapeutics (TGTX) Stock Looks Below Fair Value on Earnings
TG Therapeutics has delivered a strong share price run over the past three years, yet the stock still screens as undervalued on earnings-based multiples and only a mixed verdict on the broader valuation checks.
Over the past three years, TG Therapeutics has returned 184.5% to shareholders, which puts extra focus on whether the current valuation leaves enough room for error.
Future revenue growth from its existing treatments can support the current price. However, execution risks around...